Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent

Cardiovascular Drug Reviews

Volumn 20, Issue 2, 2002, Pages 137-152

  Wong, Pancras C ^a   Pinto, Donald J P ^a   Knabb, Robert M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Anticoagulants; Antithrombotics; Coagulation; DPC423; Factor Xa; Factor Xa inhibitors; Thrombosis

Indexed keywords

1 [3 (AMINOMETHYL)PHENYL] N [3 FLUORO 2' (METHYLSULFONYL)(1,1' BIPHENYL) 4 YL] 3 (TRIFLUOROMETHYL) 1H PYRAZOLE 5 CARBOXAMIDE; 1 [3 (AMINOMETHYL)PHENYL] N [3 FLUORO 2' (METHYLSULFONYL)[1,1' BIPHENYL] 4 YL] 3 (TRIFLUOROMETHYL) 1H PYRAZOLE 5 CARBOXAMIDE; 2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 3 [[3 [4 (AMINOIMINOMETHYL)PHENYL] 4,5 DIHYDRO 5 ISOXAZOLYL]ACETAMIDO] N [(3,5 DIMETHYL 4 ISOXAZOLYL)SULFONYL]ALANINE; ACTIVATED PROTEIN C; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9A; BLOOD CLOTTING INHIBITOR; CHYMOTRYPSIN INHIBITOR; COMPLEMENT INHIBITOR; DALTEPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; KALLIKREIN INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; PLASMIN INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN INHIBITOR; PYRAZOLE DERIVATIVE; RECOMBINANT TICK ANTICOAGULANT PEPTIDE; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTERY THROMBOSIS; BLOOD CLOTTING TIME; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; IC 50; IN VITRO STUDY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTHROMBIN TIME; RABBIT; RAT; REVIEW; THROMBOCYTE AGGREGATION;

EID: 0036387145     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2002.tb00188.x     Document Type: Review

References (27)

1. Abendschein DR, Baum PK, Martin DJ, et al. Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits. J Cardiovasc Pharmacol 2000;35:796-805.
2. Barrett JS, Davidson AF, Jiao QT, et al. The effect of food, formulation, and dosing duration on the pharmacokinetics of DPC423, a potent factor Xa inhibitor. J Clin Pharmacol 2001;41:1023.
3. Fareed J, Hoppensteadt D, Bick RL. New antithrombotic drugs: A perspective. Curr Opin Cardiovasc Pulmonary Renal Invest Drugs 1999;1:40-55.
4. Hara T, Yokoyama A, Morishima Y, Kunitada S. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb Res 1995;80:99-104.
5. Hauptmann J, Stûrzebecher J. Synthetic inhibitors of thrombin and factor Xa: From bench to bedside. Thromb Res 1999;93:203-241.
6. Hirsh J, Weitz JI. New antithrombotic agents. Lancet 1999;353:1431-1436.
7. Leadley RJ, Jr, Chi L, Rebello SS, Gagnon A. Contribution of in vivo models of thrombosis to the discovery and development of novel anti thrombotic agents. J Pharmacol Toxicol Methods 2000;43:101-116.
8. Leamy AW, Luettgen JM, Wong PC, et al. Pharmacokinetics and antithromboitc efficacy of the selective factor Xa inhibitor DPC423 in dogs. XVIII Congress of the International Society on Thrombosis and Haemostasis, July 6-12, 2001, Paris, France. Abstract P1608.
9. Mousa SA, Wityak J. Orally active isoxazoline GPIlb/Illa antagonists. Cardiovasc Drug Rev 1998;16:48-61.
10. Mutlib A, Shockcor J, Chen S-Y, et al. Formation of unusual glutamate conjugates of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2′-(methylsulfonyl)-[1, 1′-biphenyl]-4-yl]-3-(trifluoromethyl}-1H-pyrazole-5-carboxamide (DPC423) and its analogs: The role of y-glutamyltranspeptidase in the biotransformation of benzylamines. Drug Metab Dispos 2001;29:1296-1306.
11. Mutlib A, Chen S-Y, Espina R, Shockcor J, Prakash S, Gan L-S. P450-mediated metabolism of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2′-(methylsulfonyl)-[1, 1′-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423) and its analogues to aldoximes. Characterization of glutathione conjugates of postulated intermediates derived from aldoximes. Chem Res Toxicol 2002;15:63-75.
12. Mutlib A, Shockcor J, Chen S-Y, et al. Disposition of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2′-(methylsulfonyl)-[1, 1′-biphenyl]-4-yl]-3-(trifluoromethyl}-1H-pyrazole-5-carboxamide (DPC423) by novel metabolic pathways. Characterization of unusual metabolites by liquid chromatography/mass spectrometry and NMR. Chem Res Toxicol 2002;15:48-62.
13. Nagahara T, Katakura S Inanmura K, et al. DX-9065a. Drugs Future 1995;20:564-566.
14. Neeper MP, Waxman L, Smith DE, et al. Characterization of recombinant tick anticoagulant peptide. J Biol Chem 1990;265:17746-17752.
15. Peters RF, Lees CM, Mitchell KA, Tweed MF, Talbot MD, Wallis RB. The characterization of thrombus development in an improved model of arterio-venous thrombosis in the rat and the effects of recombinant desulphatohirudin (CGP 39393), heparin, and iloprost. Thromb Haemost 1991;65:268-274.
16. Pinto DJ, Orwat MJ, Wang S, et al. The discovery of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2′-(methylsulfonyl)[1, 1′-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide, a highly potent, selective and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2001;44:566-578.
17. Pruitt JR, Pinto DJ, Estrella MJ, et al. Isoxazolines and isoxazoles as factor Xa inhibitors. Biorg Med Chem Lett 2000;10:685-689.
18. Quan ML, Ellis CD, Liauw AY, et al. Design and synthesis of isoxazoline derivatives as factor Xa Inhibitors. 2. J Med Chem 1999;42:2760-2773.
19. Quan ML, Liauw AY, Ellis CD, et al. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1. J Med Chem 1999;42:2752-2759.
20. Quan ML, Pruitt JR, Ellis CD, et al. Bisbenzamidine isoxazoline derivatives as factor Xa inhibitors. Bioorg Med Chem Lett 1997;7:2813-2818.
21. Sato K, Taniuchi Y, Kawasaki T, et al. Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats. Eur J Pharmacol 1998:347:231-236.
22. Taniuchi Y, Sakai Y, Hisamichi N, et al. Biochemical and pharmacological characterization of YM-60828, a newly synthetized and orally active inhibitor of human factor Xa. Thromb Haemost 1998;79:543-548.
23. Teleha CA, Pinto DJ, Orwat MJ, Hytrek JL, Bethel YB, Taylor TL. Laboratory scale preparation of 1-aryl-3-trifluoromethyl-4-carboxamidopyrazole fXa inhibitor DPC423. 221st ACS National Meeting, April 1-4, 2001, San Diego, CA. Abstract ORG-511.
24. Wong PC, Crain EJ, Nguan O, Watson CA, Racanelli A. Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis. Thromb Res 1996;83:117-126.
25. Wong PC, Crain EJ, Knabb RM, et al. Nonpeptide factor Xa inhibitors: II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis. J Pharmacol Exp Ther 2000;295:212-218.
26. Wong PC, Quan ML, Crain EJ, Watson CA, Wexler RR, Knabb RM. Nonpeptide factor Xa inhibitors: 1. Studies with SF303 and SK549, a new class of potent antithrombotics. J Pharmacol Exp Ther 2000;292:351-357.
27. Wong PC, Crain EJ, Watson CA, et al. Antithrombotic effects of DPC423, a potent and orally active nonpeptide factor Xa inhibitor, in rabbit models of thrombosis. Circulation 2000;102:11-130.